- Home
- PHAR vs AUTL Comparison
PHAR vs AUTL Comparison
Compare PHAR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AUTL
- Stock Information
- Founded
- PHAR 1988
- AUTL 2014
- Country
- PHAR Netherlands
- AUTL United Kingdom
- Employees
- PHAR N/A
- AUTL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHAR Health Care
- AUTL Health Care
- Exchange
- PHAR Nasdaq
- AUTL Nasdaq
- Market Cap
- PHAR 618.3M
- AUTL 590.8M
- IPO Year
- PHAR N/A
- AUTL 2018
- Fundamental
- Price
- PHAR $8.42
- AUTL $2.16
- Analyst Decision
- PHAR Strong Buy
- AUTL Strong Buy
- Analyst Count
- PHAR 3
- AUTL 3
- Target Price
- PHAR $27.00
- AUTL $10.20
- AVG Volume (30 Days)
- PHAR 5.6K
- AUTL 1.1M
- Earning Date
- PHAR 03-13-2025
- AUTL 03-13-2025
- Dividend Yield
- PHAR N/A
- AUTL N/A
- EPS Growth
- PHAR N/A
- AUTL N/A
- EPS
- PHAR N/A
- AUTL N/A
- Revenue
- PHAR $285,745,000.00
- AUTL $10,091,000.00
- Revenue This Year
- PHAR $20.08
- AUTL $851.83
- Revenue Next Year
- PHAR $9.22
- AUTL $224.65
- P/E Ratio
- PHAR N/A
- AUTL N/A
- Revenue Growth
- PHAR 30.64
- AUTL 82.71
- 52 Week Low
- PHAR $6.65
- AUTL $2.07
- 52 Week High
- PHAR $13.20
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- PHAR 36.29
- AUTL 41.40
- Support Level
- PHAR $8.49
- AUTL $2.07
- Resistance Level
- PHAR $9.35
- AUTL $2.26
- Average True Range (ATR)
- PHAR 0.55
- AUTL 0.12
- MACD
- PHAR -0.17
- AUTL 0.01
- Stochastic Oscillator
- PHAR 12.14
- AUTL 25.00
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.